Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
56.95
-4.06 (-6.65%)
Nov 7, 2025, 11:47 AM EST - Market open
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $2.76M in the quarter ending September 30, 2025, a decrease of -26.12%. This brings the company's revenue in the last twelve months to $43.74M, down -50.05% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$43.74M
Revenue Growth
-50.05%
P/S Ratio
114.42
Revenue / Employee
$232,633
Employees
188
Market Cap
4.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KYMR News
- 2 days ago - Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Kymera Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 10 days ago - Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 11 days ago - Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting - GlobeNewsWire
- 2 months ago - Kymera Therapeutics, Inc. (KYMR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 2 months ago - Kymera Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire